BRIGHT PEAK
LIVE

Serial Number

79285070

Owner

Bright Peak Therapeutics AG

Attorney

Monica Riva Talley

Filing Date

Mar 25, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BRIGHT PEAK Trademark

Serial Number: 79285070 • Registration: 6610085

BRIGHT PEAK is a trademark filed by Bright Peak Therapeutics AG on March 25, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Bright Peak Therapeutics AG

Aeschenvorstadt 36

Entity Type: 99

Trademark Details

Filing Date

March 25, 2020

Registration Date

January 11, 2022

Published for Opposition

October 26, 2021

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; medical and veterinary preparations, namely, recombinant or chemically synthesized and optimized proteins; preparations for destroying vermin; fungicides, herbicides; biotechnological preparations, namely, recombinant or chemically synthesized and optimized proteins for medical use; enzymes for medical use; enzymes for veterinary use; biological and chemical reagents for medical or veterinary use; amino acids for medical use; amino acids for veterinary use; peptides for medical or veterinary use, namely, for the treatment of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; proteins for medical or veterinary use, namely, recombinant or chemically synthesized and optimized proteins for detection and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, nutritional diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; pharmaceutical preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical compositions and preparations for cancer prevention and treatment; pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; pharmaceutical preparations for treatment of skin diseases; pharmaceutical preparations for treatment of neurodegenerative, metabolic and ophthalmological diseases

Scientific and technological services, namely, scientific research, scientific analysis, and scientific testing in the field of biotechnology and new product research and design services relating thereto; research and development in the field of biotechnology; consulting services in the field of biotechnology; scientific research services in the field of proteins, peptides and antibodies, and scientific advice relating thereto; scientific research services for medical purposes in the field of cancer and autoimmune diseases and scientific advice relating thereto

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 18, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 23, 2022 FICS
FINAL DISPOSITION PROCESSED
Jun 22, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 11, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 11, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Nov 4, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 3, 2021 OPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 26, 2021 NPUB
PUBLISHED FOR OPPOSITION
Oct 26, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 13, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 13, 2021 OPNR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 6, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 6, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 6, 2021 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 17, 2021 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 17, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 24, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 24, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 24, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 24, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 29, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 29, 2021 CRFA
ASSIGNED TO LIE
Jul 27, 2021 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 22, 2021 ERFR
EX PARTE APPEAL-INSTITUTED
Jul 22, 2021 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jul 22, 2021 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jul 22, 2021 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 26, 2021 GNFN
FINAL REFUSAL E-MAILED
Jan 26, 2021 GNFR
FINAL REFUSAL WRITTEN
Jan 26, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 6, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 5, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 5, 2021 TROA
REFUSAL PROCESSED BY IB
Aug 7, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 23, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jul 23, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 18, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jun 17, 2020 CNRT
ASSIGNED TO EXAMINER
Jun 16, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
May 12, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 8, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 7, 2020 REPR